The Experts below are selected from a list of 159 Experts worldwide ranked by ideXlab platform
Jjghm Bergman - One of the best experts on this subject based on the ideXlab platform.
-
Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases.
United European gastroenterology journal, 2018Co-Authors: M J Van Der Wel, Lucas C. Duits, Esther Klaver, R. E. Pouw, C. A. Seldenrijk, G. J. A. Offerhaus, Mike Visser, Fjw Ten Kate, J. G. P. Tijssen, Jjghm BergmanAbstract:Background: Dysplasia in Barrett's Esophagus (BE) biopsies is associated with low observer agreement among general pathologists. Therefore, expert review is advised. We are developing a web-based, national expert review panel for histological review of BE biopsies. Objective: The aim of this study was to create benchmark quality criteria for future members. Methods: Five expert BE pathologists, with 10–30 years of BE experience, weekly handling 5–10 cases (25% dysplastic), assessed a case set of 60 digitalized cases, enriched for dysplasia. Each case contained all slides from one endoscopy (non-dysplastic BE (NDBE), n = 21; low-grade dysplasia (LGD), n = 20; high-grade dysplasia (HGD), n = 19). All cases were randomized and assessed twice followed by group discussions to create a consensus diagnosis. Outcome measures: percentage of ‘indefinite for dysplasia’ (IND) diagnoses, intra-observer agreement, and agreement with the consensus ‘gold standard’ diagnosis. Results: Mean percentage of IND diagnoses was 8% (3–14%) and mean intra-observer agreement was 0.84 (0.66–1.02). Mean agreement with the consensus diagnosis was 90% (95% prediction interval (PI) 82–98%). Conclusion: Expert pathology review of BE requires the scoring of a limited number of IND cases, consistency of assessment and a high agreement with a consensus gold standard diagnosis. These benchmark quality criteria will be used to assess the performance of other pathologists joining our panel.
-
Supplementary Table 2 -Supplemental material for Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases
2018Co-Authors: M J Van Der Wel, Lucas C. Duits, Esther Klaver, R. E. Pouw, C. A. Seldenrijk, G. J. A. Offerhaus, Mike Visser, Fjw Ten Kate, J. G. P. Tijssen, Jjghm BergmanAbstract:Supplemental material, Supplementary Table 2 for Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases by MJ van der Wel, LC Duits, E Klaver, RE Pouw, CA Seldenrijk, GJA Offerhaus, M Visser, FJW ten Kate, JG Tijssen, JJGHM Bergman and SL Meijer in United European Gastroenterology Journal
-
Characterization of tissue autofluorescence in Barrett's Esophagus by confocal fluorescence microscopy.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2007Co-Authors: Mohammed A. Kara, Jjghm Bergman, Ralph S. Dacosta, Catherine J. Streutker, Norman E. Marcon, Brian C. WilsonAbstract:High grade dysplasia and early cancer in Barrett's Esophagus can be distinguished in vivo by endoscopic autofluorescence point spectroscopy and imaging from non-dysplastic Barrett's mucosa. We used confocal fluorescence microscopy for ex vivo comparison of autofluorescence in non-dysplastic and dysplastic Barrett's Esophagus. Unstained frozen sections were obtained from snap-frozen Barrett's Esophagus Biopsy samples and scanned with confocal fluorescence microscopy (458 nm excitation; 505-550 nm [green] and > 560 nm [red] emission). Digital micrographs were taken from areas with homogenous and specific histopathology. Visual inspection and statistical analysis were used to evaluate the image datasets. Dysplastic and non-dysplastic Barrett's Esophagus epithelia fluoresced mainly in the green spectrum and the main sources of autofluorescence were the cytoplasm and lamina propria. High-grade dysplasia was differentiated from non-dysplastic Barrett's Esophagus by microstructural tissue changes. However, there were no specific changes in either the locations or average intensities of intrinsic green and red autofluorescence at the epithelial level that could differentiate between dysplastic and non-dysplastic Barrett's Esophagus epithelia, ex vivo. Detectable differences in autofluorescence between BE and dysplasia/cancer in vivo are probably not caused by specific changes in epithelial fluorophores but are likely due to other inherent changes (e.g. mucosal thickening and increased microvascularity) attenuating autofluorescence from the collagen-rich submucosa. Furthermore, confocal fluorescence microscopy provides 'histology-like' imaging of Barrett's tissues and may offer a unique opportunity to exploit microstructural tissue changes occurring during neoplastic transformation for in vivo detection of high-grade dysplasia in Barrett's patients using newly developed confocal fluorescence microendoscopy devices
M J Van Der Wel - One of the best experts on this subject based on the ideXlab platform.
-
Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases.
United European gastroenterology journal, 2018Co-Authors: M J Van Der Wel, Lucas C. Duits, Esther Klaver, R. E. Pouw, C. A. Seldenrijk, G. J. A. Offerhaus, Mike Visser, Fjw Ten Kate, J. G. P. Tijssen, Jjghm BergmanAbstract:Background: Dysplasia in Barrett's Esophagus (BE) biopsies is associated with low observer agreement among general pathologists. Therefore, expert review is advised. We are developing a web-based, national expert review panel for histological review of BE biopsies. Objective: The aim of this study was to create benchmark quality criteria for future members. Methods: Five expert BE pathologists, with 10–30 years of BE experience, weekly handling 5–10 cases (25% dysplastic), assessed a case set of 60 digitalized cases, enriched for dysplasia. Each case contained all slides from one endoscopy (non-dysplastic BE (NDBE), n = 21; low-grade dysplasia (LGD), n = 20; high-grade dysplasia (HGD), n = 19). All cases were randomized and assessed twice followed by group discussions to create a consensus diagnosis. Outcome measures: percentage of ‘indefinite for dysplasia’ (IND) diagnoses, intra-observer agreement, and agreement with the consensus ‘gold standard’ diagnosis. Results: Mean percentage of IND diagnoses was 8% (3–14%) and mean intra-observer agreement was 0.84 (0.66–1.02). Mean agreement with the consensus diagnosis was 90% (95% prediction interval (PI) 82–98%). Conclusion: Expert pathology review of BE requires the scoring of a limited number of IND cases, consistency of assessment and a high agreement with a consensus gold standard diagnosis. These benchmark quality criteria will be used to assess the performance of other pathologists joining our panel.
-
Supplementary Table 2 -Supplemental material for Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases
2018Co-Authors: M J Van Der Wel, Lucas C. Duits, Esther Klaver, R. E. Pouw, C. A. Seldenrijk, G. J. A. Offerhaus, Mike Visser, Fjw Ten Kate, J. G. P. Tijssen, Jjghm BergmanAbstract:Supplemental material, Supplementary Table 2 for Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases by MJ van der Wel, LC Duits, E Klaver, RE Pouw, CA Seldenrijk, GJA Offerhaus, M Visser, FJW ten Kate, JG Tijssen, JJGHM Bergman and SL Meijer in United European Gastroenterology Journal
Tom R. Demeester - One of the best experts on this subject based on the ideXlab platform.
-
The dilated distal Esophagus: a new entity that is the pathologic basis of early gastroesophageal reflux disease.
The American journal of surgical pathology, 2011Co-Authors: Parakrama Chandrasoma, S Wijetunge, Steven R. Demeester, Jeffrey A. Hagen, Tom R. DemeesterAbstract:Present management algorithms for patients with gastroesophageal reflux disease (GERD) limit endoscopy to patients with advanced disease. When endoscopy is performed, Biopsy is limited to patients who have a visible columnar-lined Esophagus. Biopsy is not recommended for patients whose endoscopy is
K. C. Allman - One of the best experts on this subject based on the ideXlab platform.
-
Bone scintigraphy in an uncommon presentation of metastatic lung carcinoma
Clinical nuclear medicine, 1997Co-Authors: Geoffrey Storey, Lucy Morgan, Matthew J. Peters, P J Kennedy, H. Van Der Wall, K. C. AllmanAbstract:A 66-year-old male smoker with a history of peptic ulcer disease had hemoptysis and weight loss. Bronchoscopy revealed a tumor in the right main bronchus. Thoracic CT scan showed a right hilar mass with tumor extension into the Esophagus. Biopsy of the tumor confirmed squamous cell carcinoma. The patient underwent radical radiotherapy plus adjuvant chemotherapy. Four months later, left maxillary pain with local swelling and loosening of teeth developed, which progressed despite parenteral antibiotic therapy. A bone scan revealed diffuse symmetric increase in tracer accumulation throughout the maxilla. CT scan showed extensive palatal destruction by tumor. Maxillary Biopsy confirmed squamous cell carcinoma with histologic features consistent with metastasis from the primary lung carcinoma.
Esther Klaver - One of the best experts on this subject based on the ideXlab platform.
-
Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases.
United European gastroenterology journal, 2018Co-Authors: M J Van Der Wel, Lucas C. Duits, Esther Klaver, R. E. Pouw, C. A. Seldenrijk, G. J. A. Offerhaus, Mike Visser, Fjw Ten Kate, J. G. P. Tijssen, Jjghm BergmanAbstract:Background: Dysplasia in Barrett's Esophagus (BE) biopsies is associated with low observer agreement among general pathologists. Therefore, expert review is advised. We are developing a web-based, national expert review panel for histological review of BE biopsies. Objective: The aim of this study was to create benchmark quality criteria for future members. Methods: Five expert BE pathologists, with 10–30 years of BE experience, weekly handling 5–10 cases (25% dysplastic), assessed a case set of 60 digitalized cases, enriched for dysplasia. Each case contained all slides from one endoscopy (non-dysplastic BE (NDBE), n = 21; low-grade dysplasia (LGD), n = 20; high-grade dysplasia (HGD), n = 19). All cases were randomized and assessed twice followed by group discussions to create a consensus diagnosis. Outcome measures: percentage of ‘indefinite for dysplasia’ (IND) diagnoses, intra-observer agreement, and agreement with the consensus ‘gold standard’ diagnosis. Results: Mean percentage of IND diagnoses was 8% (3–14%) and mean intra-observer agreement was 0.84 (0.66–1.02). Mean agreement with the consensus diagnosis was 90% (95% prediction interval (PI) 82–98%). Conclusion: Expert pathology review of BE requires the scoring of a limited number of IND cases, consistency of assessment and a high agreement with a consensus gold standard diagnosis. These benchmark quality criteria will be used to assess the performance of other pathologists joining our panel.
-
Supplementary Table 2 -Supplemental material for Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases
2018Co-Authors: M J Van Der Wel, Lucas C. Duits, Esther Klaver, R. E. Pouw, C. A. Seldenrijk, G. J. A. Offerhaus, Mike Visser, Fjw Ten Kate, J. G. P. Tijssen, Jjghm BergmanAbstract:Supplemental material, Supplementary Table 2 for Development of benchmark quality criteria for assessing whole-endoscopy Barrett's Esophagus Biopsy cases by MJ van der Wel, LC Duits, E Klaver, RE Pouw, CA Seldenrijk, GJA Offerhaus, M Visser, FJW ten Kate, JG Tijssen, JJGHM Bergman and SL Meijer in United European Gastroenterology Journal